CRP and periodontitis: Resolvins, including resolving D1 and resolving E1, have been shown in preclinical and animal models to demonstrated to inhibit the destructive inflammatory process and alveolar bone loss in laboratory-induced periodontitis under controlled experimental conditions (73) and have been shown to reduce systemic pro-inflammatory mediators, such as C-reactive protein (CRP) and interleukin-1β after periodontal treatment and adjunctive resolving use (74).